Skip to main content

Table 5 Univariate and Multivariate analysis of PFS

From: Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

 

Cases

   

Univariate

Multivariate

  

1-yr survival rate(%)

2-yr survival rate(%)

Median survival(mo)

P-Value

ExpB (Hazard Ratio ,95 % CI)

P-Value

Gender

       

 Male

130

47

26

10.79

0.331

  

 Female

12

37

0

6.11

   

Age

       

  < 60

92

49

29

10.49

0.180

  

  ≥ 60

50

40

21

9.35

   

Alpha-foetoprotein(ng/ml)

       

  ≤ 20

42

50

44

11.99

0.445

  

 20–400

37

35

8

7.03

   

  ≥ 400

63

51

28

8.37

   

Child Pugh grade

    

0.047

2.852(1.002–8.293)

0.050

 A

133

48

28

10.56

   

 B

9

22

0

7.07

   

ALB(g/L)

    

0.307

  

  ≥ 35

108

46

20

10.49

   

  < 35

34

47

47

10.25

   

Tbil(U/L)

    

0.429

  

  < 20

104

49

23

11.18

   

  ≥ 20

38

37

32

6.21

   

Platelet count (10E9/L)

       

  < 100

19

74

32

13.57

0.144

  

  ≥ 100

123

42

25

9.83

   

No. of tumours

    

0.034

3.992(1.978–8.057)

0.001

  ≤ 3

118

51

28

11.04

   

  > 3

24

21

14

7.6

   

Tumour size (cm)

    

0.988

2.667(1.041–6.832)

0.041

  ≤ 5

35

39

24

11.37

   

  > 5

107

48

25

8.37

   

Virus infection

    

0.079

  

 none

14

59

59

13.05

   

 HBV

126

43

24

10.25

   

 HCV

2

50

0

11.30

   

Anti-virus therapy

    

0.951

  

 Yes

33

44

30

8.37

   

 No

95

43

22

10.56

   

H101

    

0.051

0.461(0.244–0.870)

0.017

 Yes

74

51

32

10.49

   

 No

68

41

20

9.72